Previous Close | 0.3335 |
Open | 0.3495 |
Bid | 0.3576 x 3100 |
Ask | 0.3649 x 800 |
Day's Range | 0.3432 - 0.3729 |
52 Week Range | 0.2600 - 4.0000 |
Volume | |
Avg. Volume | 1,723,953 |
Market Cap | 21.805M |
Beta (5Y Monthly) | 2.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -9.2600 |
Earnings Date | Mar 19, 2024 - Mar 24, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.63 |
Subscribe to Yahoo Finance Plus to view Fair Value for TNXP
Zembrace® SymTouch® and Tosymra® will be marketed by Tonix Medicines, Tonix’s wholly-owned commercial subsidiary Commercial capabilities prepare Tonix for the potential launch in 2025 of Tonmya™ for the management of fibromyalgia, assuming FDA approval CHATHAM, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will
Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia In the U.S., New Drug Application (NDA) submission to the FDA planned for the second half of 2024 In Japan, China and most countries in Europe cyclobenzaprine is a New Chemical Entity CHATHAM, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of developme
By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update Two New FDA Approved Fibromyalgia Treatments Possible in 2025 In the second half of 2024, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) will be filing a new drug application (NDA) for TNX-102 SL (conditionally accepted trade name Tonmya™) for the treatment of fibromyalgia. The filing will be based in part on